Development and Characterization of a Wee1 Kinase Degrader
Tóm tắt
Từ khóa
Tài liệu tham khảo
Beck, 2012, Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption, Mol. Cell Biol., 32, 4226, 10.1128/MCB.00412-12
Bondeson, 2018, Lessons in PROTAC design from selective degradation with a promiscuous warhead, Cell Chem. Biol., 25, 78, 10.1016/j.chembiol.2017.09.010
Carrassa, 2017, DNA damage response inhibitors: mechanisms and potential applications in cancer therapy, Cancer Treat. Rev., 60, 139, 10.1016/j.ctrv.2017.08.013
Chamberlain, 2014, Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs, Nat. Struct. Mol. Biol., 21, 803, 10.1038/nsmb.2874
Chanan-Khan, 2013, Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma, Blood Cancer J., 3, e143, 10.1038/bcj.2013.38
Chen, 2018, Wee1 inhibitor AZD1775 combined with cisplatin potentiates anticancer activity against gastric cancer by increasing DNA damage and cell apoptosis, Biomed. Res. Int., 2018, 5813292
Di Rora, 2018, Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia, J. Hematol. Oncol., 11, 99, 10.1186/s13045-018-0641-1
Do, 2015, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, J. Clin. Oncol., 33, 3409, 10.1200/JCO.2014.60.4009
Dobrovolsky, 2019, Bruton tyrosine kinase degradation as a therapeutic strategy for cancer, Blood, 133, 952, 10.1182/blood-2018-07-862953
Donovan, 2018, Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome, Elife, 7, e38430, 10.7554/eLife.38430
Fang, 2019, Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy, Cancer Cell, 35, 851, 10.1016/j.ccell.2019.05.001
Fu, 2018, Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy, Expert Opin. Investig. Drugs, 27, 741, 10.1080/13543784.2018.1511700
Guertin, 2013, Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy, Mol. Cancer Ther., 12, 1442, 10.1158/1535-7163.MCT-13-0025
Hafner, 2016, Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs, Nat. Methods, 13, 521, 10.1038/nmeth.3853
Hirai, 2009, Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents, Mol. Cancer Ther., 8, 2992, 10.1158/1535-7163.MCT-09-0463
Huang, 2018, A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader, Cell Chem Biol., 25, 88, 10.1016/j.chembiol.2017.10.005
Jiang, 2019, Development of dual and selective degraders of cyclin-dependent kinases 4 and 6, Angew. Chem. Int. Ed., 58, 6321, 10.1002/anie.201901336
Kim, 2015, FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy, Clin. Cancer Res., 21, 4257, 10.1158/1078-0432.CCR-15-0887
Krönke, 2014, Lenalidomide induces degradation of IKZF1 and IKZF3, Oncoimmunology, 3, e941742, 10.4161/21624011.2014.941742
Leijen, 2016, Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, Cisplatin, or Carboplatin in patients with advanced solid tumors, J. Clin. Oncol., 34, 4371, 10.1200/JCO.2016.67.5991
Matheson, 2016, Targeting WEE1 kinase in cancer, Trends Pharmacol. Sci., 37, 872, 10.1016/j.tips.2016.06.006
Matheson, 2016, A WEE1 inhibitor analog of AZD1775 maintains synergy with cisplatin and demonstrates reduced single-agent cytotoxicity in medulloblastoma cells, ACS Chem. Biol., 11, 921, 10.1021/acschembio.5b00725
Matheson, 2018, Development of potent pyrazolopyrimidinone-based WEE1 inhibitors with limited single-agent cytotoxicity for cancer therapy, Chemmedchem, 13, 1681, 10.1002/cmdc.201800188
McAlister, 2014, MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes, Anal. Chem., 86, 7150, 10.1021/ac502040v
Meng, 2018, AZD1775 increases sensitivity to Olaparib and gemcitabine in cancer cells with p53 mutations, Cancers (Basel), 10, 149, 10.3390/cancers10050149
National Institutes of Health. AZD1775 Combined with Olaparib in Patients with Refractory Solid Tumors. Available at https://clinicaltrials.gov/ct2/show/NCT02511795. Accessed November 10, 2019.
Nowak, 2018, Plasticity in binding confers selectivity in ligand-induced protein degradation, Nat. Chem. Biol., 14, 706, 10.1038/s41589-018-0055-y
Olson, 2017, Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation, Nat. Chem. Biol., 14, 163, 10.1038/nchembio.2538
Pettersson, 2019, PROteolysis TArgeting Chimeras (PROTACs)––past, present and future, Drug Discov. Today Technol., 31, 15, 10.1016/j.ddtec.2019.01.002
Ritchie, 2015, Limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res., 43, e47, 10.1093/nar/gkv007
Schmidt, 2017, Regulation of G2/M transition by inhibition of WEE1 and PKMYT1 kinases, Molecules, 22, 10.3390/molecules22122045
Toure, 2016, Small-molecule PROTACS: new approaches to protein degradation, Angew. Chem. Int. Ed., 55, 1966, 10.1002/anie.201507978
Winter, 2015, Phthalimide conjugation as a strategy for in vivo target protein degradation, Science, 348, 1376, 10.1126/science.aab1433
Winter, 2017, BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment, Mol. Cell, 67, 5, 10.1016/j.molcel.2017.06.004
Wright, 2017, Dual targeting of WEE1 and PLK1 by AZD1775 elicits single agent cellular anticancer activity, ACS Chem. Biol., 12, 1883, 10.1021/acschembio.7b00147
Yu, 2016, High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines, Nat. Biotechnol., 34, 419, 10.1038/nbt.3460